Click here to view online. Add this email to your safelist.
AstraZeneca to share latest data from an industry-leading portfolio that aims to advance clinical understanding of diabetes and CV risk management at ADA 2018
19 June 2018
AstraZeneca and its global biologics research and development arm, MedImmune, will present 45 abstracts including seven late-breaking data disclosures from the Company’s Cardiovascular, Renal & Metabolism (CVRM) therapy area at the American Diabetes Association’s (ADA) 78th Scientific Sessions in Orlando, Florida, 22-26 June 2018.
|
|||||
|
|||||
|
For more information please visit astrazeneca.com. If you would like to unsubscribe please click here. |
